Skip to main content
Erschienen in: Netherlands Heart Journal 4/2009

01.04.2009 | Original article

Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events

verfasst von: D. J. Mulder, P. L. van Haelst, R. Graaff, R. O. Gans, F. Zijlstra, A. J. Smit

Erschienen in: Netherlands Heart Journal | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Background.ST-elevation myocardial infarction (STEMI) is associated with increased inflammation and oxidative stress, enhancing the formation of advanced glycation endproducts (AGEs). These encompass a characteristic fluorescence pattern, which can be non-invasively measured as skin autofluorescence (AF). In this study we investigate whether skin AF is elevated in STEMI, its association with inflammatory and glycaemic stress and its predictive value for future events.
Methods.Skin AF was measured in 88 STEMI patients (mean age 64±13 years) within 72 hours and around six months after discharge, in 81 stable coronary artery disease (sCAD) patients (64±10 years), and in 32 healthy controls (63±11 years). The cumulative one-year incidence of all-cause mortality and hospitalisation for myocardial infarction or heart failure was documented.
Results.Skin AF was significantly higher in STEMI compared with sCAD and controls, irrespective of confounders, and was associated with HbA1c and C-reactive protein. Skin AF decreased significantly in STEMI patients, when measured >200 days after discharge. In STEMI patients, skin AF above the median was predictive of future events (hazard ratio 11.6, 95% CI 1.5 to 90.8, p=0.019).
Conclusion.Skin AF is elevated in STEMI, is associated with inflammation and glycaemic stress, and predicts future major adverse cardiac events. (Neth Heart J 2009;17:162–8.)
Literatur
1.
Zurück zum Zitat Stocker R, Keaney J. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381–478. Stocker R, Keaney J. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381–478.
2.
Zurück zum Zitat Walter M, Jacob R, Jeffers B, Ghadanfar M, Preston G, Buch J, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol 2004;44:1996–2002. Walter M, Jacob R, Jeffers B, Ghadanfar M, Preston G, Buch J, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol 2004;44:1996–2002.
3.
Zurück zum Zitat Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104: 2673–8. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104: 2673–8.
4.
Zurück zum Zitat Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999;281: 1718–21. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999;281: 1718–21.
5.
Zurück zum Zitat Shimomura H, Ogawa H, Takazoe K, Soejima H, Miyamoto S, Sakamoto T, et al. Comparison of urinary biopyrrin levels in acute myocardial infarction (after reperfusion therapy) versus stable angina pectoris and their usefulness in predicting subsequent cardiac events. Am J Cardiol 2002;90:108–111. Shimomura H, Ogawa H, Takazoe K, Soejima H, Miyamoto S, Sakamoto T, et al. Comparison of urinary biopyrrin levels in acute myocardial infarction (after reperfusion therapy) versus stable angina pectoris and their usefulness in predicting subsequent cardiac events. Am J Cardiol 2002;90:108–111.
6.
Zurück zum Zitat Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, et al. Urinary 8-iso-Prostaglandin F2{alpha} as a risk marker in patients with coronary heart disease: A matched casecontrol study. Circulation 2004; 109:843–8. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, et al. Urinary 8-iso-Prostaglandin F2{alpha} as a risk marker in patients with coronary heart disease: A matched casecontrol study. Circulation 2004; 109:843–8.
7.
Zurück zum Zitat Smit A, Lutgers H. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004;11:2767–84. Smit A, Lutgers H. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004;11:2767–84.
8.
Zurück zum Zitat Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28:1708–16. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28:1708–16.
9.
Zurück zum Zitat Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687–93. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687–93.
10.
Zurück zum Zitat Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007;30:107–12. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007;30:107–12.
11.
Zurück zum Zitat Mulder DJ, van Haelst PL, Gross S, de LK, Bijzet J, Graaff R, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2007;197:217–23. Mulder DJ, van Haelst PL, Gross S, de LK, Bijzet J, Graaff R, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2007;197:217–23.
12.
Zurück zum Zitat Meerwaldt R, Oomen PHN, Links TP, Gans ROB, Smit AJ, Graaff R, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324–30. Meerwaldt R, Oomen PHN, Links TP, Gans ROB, Smit AJ, Graaff R, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324–30.
13.
Zurück zum Zitat Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, et al. Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 2005;1043:290–8. Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, et al. Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 2005;1043:290–8.
14.
Zurück zum Zitat Mulder DJ, van Haelst PL, Graaff R, Smit AJ, Gans RO, Zijlstra F. Skin autofluorescence is an independent marker for acute myocardial infarction. Circulation 2005;112:U427. Mulder DJ, van Haelst PL, Graaff R, Smit AJ, Gans RO, Zijlstra F. Skin autofluorescence is an independent marker for acute myocardial infarction. Circulation 2005;112:U427.
15.
Zurück zum Zitat Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982–6. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982–6.
16.
Zurück zum Zitat Hartog J, de Vries A, Lutgers H, Meerwaldt R, Huisman R, van Son W, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005;1043:299–307. Hartog J, de Vries A, Lutgers H, Meerwaldt R, Huisman R, van Son W, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005;1043:299–307.
17.
Zurück zum Zitat Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654–9. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654–9.
18.
Zurück zum Zitat Meerwaldt R, Graaff R, Links T, Baynes JW, Navis G, Huisman R, et al. Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of mortality in hemodialysis patients. Ann N Y Acad Sci 2005;1043:911. Meerwaldt R, Graaff R, Links T, Baynes JW, Navis G, Huisman R, et al. Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of mortality in hemodialysis patients. Ann N Y Acad Sci 2005;1043:911.
19.
Zurück zum Zitat Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Macri G, et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys 2003;420:255–61. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Macri G, et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys 2003;420:255–61.
20.
Zurück zum Zitat Horiuchi M, Tsutsui M, Tasaki H, Morishita T, Suda O, Nakata S, et al. Upregulation of vascular extracellular superoxide dismutase in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 2004;24:106–11. Horiuchi M, Tsutsui M, Tasaki H, Morishita T, Suda O, Nakata S, et al. Upregulation of vascular extracellular superoxide dismutase in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 2004;24:106–11.
21.
Zurück zum Zitat Wang XL, Adachi T, Sim AS, Wilcken DEL. Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18: 1915–21. Wang XL, Adachi T, Sim AS, Wilcken DEL. Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18: 1915–21.
22.
Zurück zum Zitat Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256:308–15. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256:308–15.
23.
Zurück zum Zitat Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109:IV6–19. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109:IV6–19.
24.
Zurück zum Zitat Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001;24:1620. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001;24:1620.
25.
Zurück zum Zitat Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005;25: 815–20. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005;25: 815–20.
26.
Zurück zum Zitat Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37: 586–600. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37: 586–600.
27.
Zurück zum Zitat Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006; 113:1226–34. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006; 113:1226–34.
28.
Zurück zum Zitat Forbes J, Yee L, Thallas V, Lassila M, Candido R, Jandeleit-Dahm K, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813–23. Forbes J, Yee L, Thallas V, Lassila M, Candido R, Jandeleit-Dahm K, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813–23.
29.
Zurück zum Zitat Park L, Raman K, Lee K, Lu Y, Ferran L, Chow W, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025–31. Park L, Raman K, Lee K, Lu Y, Ferran L, Chow W, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025–31.
30.
Zurück zum Zitat Wolffenbuttel BHR, Crijns FRL, Huijberts MSP, Swennen GNM, Boulanger CM, Poitevin P et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630–4. Wolffenbuttel BHR, Crijns FRL, Huijberts MSP, Swennen GNM, Boulanger CM, Poitevin P et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630–4.
31.
Zurück zum Zitat Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002;99:15596–601. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002;99:15596–601.
32.
Zurück zum Zitat Liuzzo G, Biasucci LM, Rebuzzi AG, Maseri A, Grillo RL, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417–24. Liuzzo G, Biasucci LM, Rebuzzi AG, Maseri A, Grillo RL, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417–24.
33.
Zurück zum Zitat Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006;8:523–35. Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006;8:523–35.
34.
Zurück zum Zitat Odetti P, Pronzato MA, Noberasco G, Cosso L, Traverso N, Cottalasso D, et al. Relationships between glycation and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study. Lab Invest 1994;70:61–7. Odetti P, Pronzato MA, Noberasco G, Cosso L, Traverso N, Cottalasso D, et al. Relationships between glycation and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study. Lab Invest 1994;70:61–7.
Metadaten
Titel
Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events
verfasst von
D. J. Mulder
P. L. van Haelst
R. Graaff
R. O. Gans
F. Zijlstra
A. J. Smit
Publikationsdatum
01.04.2009
Verlag
Bohn Stafleu van Loghum
Erschienen in
Netherlands Heart Journal / Ausgabe 4/2009
Print ISSN: 1568-5888
Elektronische ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086239

Weitere Artikel der Ausgabe 4/2009

Netherlands Heart Journal 4/2009 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.